In clinical trials
Brain & sleep
Trofinetide (predecessor programs)
Evidence
Clinical trials
Class
IGF-1 fragment peptides (GPE and analogs)
KEY TAKEAWAY
This entry covers the earlier research on glycine-proline-glutamate (GPE), a natural fragment of IGF-1, and related analogs that led to trofinetide. These earlier compounds are not FDA-approved. Trofinetide (Daybue), the program that reached approval, treats Rett syndrome.
Written by the Veylo editorial team · Updated
November 2026
What it is
IGF-1 fragment peptides (GPE and analogs)
Being studied for
Studied in brain injury and neurodegeneration models
Key fact
These earlier compounds are not FDA-approved. Trofinetide (Daybue), the program that reached approval, treats Rett syndrome.
Route
Varied by research program
Evidence strength
Clinical trials
This entry covers the earlier research on glycine-proline-glutamate (GPE), a natural fragment of IGF-1, and related analogs that led to trofinetide.
GPE and its analogs were studied for protecting nerve cells after injury and in neurodegenerative conditions, mostly in laboratory and animal models.
These earlier compounds are not FDA-approved. Trofinetide (Daybue), the program that reached approval, treats Rett syndrome.
Studied in brain injury and neurodegeneration models.
Because these programs were mostly preclinical or early phase, human safety data are limited.
Trofinetide (predecessor programs): see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.